Sepracor's partnership with ACADIA Pharmaceuticals, potentially worth US$95 M, has been forged to develop new drug candidates against CNS disorders, including sleep-related indications and schizophrenia. The collaboration will also determine whether certain ACADIA CNS projects could be advanced into clinical development.